Article Text

Download PDFPDF
HNRNPA1, a Splicing Regulator, Is an Effective Target Protein for Cervical Cancer Detection: Comparison With Conventional Tumor Markers
  1. Young-Jon Kim, MD,
  2. Byoung-Ryun Kim, MD,
  3. Jae-Suk Ryu,
  4. Gyeong-Ok Lee, MSc,
  5. Hak-Ryul Kim, MD,
  6. Keum-Ha Choi, MD,
  7. Jae-Won Ryu,
  8. Kyoung-Suk Na, MSc,
  9. Min-Cheol Park, PhD,
  10. Hong-Seob So, PhD,
  11. Ji-Hyun Cho, MD and
  12. Do-Sim Park, MD
  1. * Department of Family Medicine, School of Medicine,
  2. Department of Obstetrics and Gynecology, School of Medicine,
  3. Department of Laboratory Medicine, School of Medicine,
  4. § Division of Biological Science, College of Natural Sciences,
  5. Department of Internal Medicine, School of Medicine,
  6. Department of Pathology, School of Medicine,
  7. # Department of Herbology, School of Oriental Medicine, and
  8. ** Department of Microbiology, School of Medicine, Wonkwang University; and
  9. †† Wonkwang Institute of Clinical Medicine, Wonkwang University Hospital, Iksan, Korea.
  1. Address correspondence and reprint requests to Do-Sim Park, MD, PhD, Department of Laboratory Medicine, Wonkwang University Hospital, 895 Muwang-ro, Iksan 54538, Republic of Korea. E-mail: emailds{at}hanmail.net.

Abstract

Objective Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1), serine/arginine-rich splicing factor 1 (SRSF1), and SRSF3 are splicing regulators associated with oncogenesis. However, the alterations of SF proteins and their diagnostic values in cervical cancer are unclear. To apply SFs clinically, effective marker selection and characterization of the target organ properties are essential.

Materials and Methods We concurrently analyzed HNRNPA1, SRSF1, SRSF3, and the conventional tumor markers squamous cell carcinoma antigen (SCCA) and carcinoembryonic antigen (CEA) in cervical tissue samples (n = 127) using semiquantitative immunoblotting. In addition, we compared them with p16 (cyclin-dependent kinase inhibitor 2A [CDKN2A]), which has shown high diagnostic efficacy in immunohistochemical staining studies and has been proposed as a candidate protein for point-of-care screening biochemical tests of cervical neoplasia.

Results HNRNPA1, higher molecular weight forms of SRSF1 (SRSF1-HMws), SRSF3, CEA, and p16 levels were higher (P < 0.05) in cervical carcinoma tissue samples than in nontumoral cervical tissue samples. However, the levels of SRSF1-Total (sum of SRSF1-HMws and a lower molecular weight form of SRSF1) and SCCA, a commonly used cervical tumor marker, were not different between carcinoma and nontumoral tissue samples. In paired sample comparisons, HNRNPA1 (94%) showed the highest incidence of up-regulation (carcinoma/nontumor, >1.5) in cervical carcinoma, followed by p16 (84%), SRSF1-HMws (69%), SRSF3 (66%), CEA (66 %), SCCA (32%), and SRSF1-Total (31%). HNRNPA1 (92%) and p16 (91%) presented the two highest diagnostic accuracies for cervical carcinoma, which were superior to those of SRSF3 (75%), SRSF1-HMws (72%), CEA (72%), SCCA (59%), and SRSF1-Total (55%).

Conclusions Our results identified that HNRNPA1 is the best diagnostic marker among the SFs and conventional markers given its excellent diagnostic efficacy for cervical carcinoma, and it has a p16-comparable diagnostic value. We suggest that HNRNPA1 is an additional effective target protein for developing cervical cancer detection tools.

  • Cervical cancer
  • Tumor marker
  • HNRNPA1
  • SRSF1
  • SRSF3

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflict of interests.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.